| Nome |
# |
|
Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells, file e309ade2-a7ce-3969-e053-3a05fe0a2c94
|
1.333
|
|
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia (letter), file e309ade4-268c-3969-e053-3a05fe0a2c94
|
200
|
|
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia, file e309ade4-a939-3969-e053-3a05fe0a2c94
|
189
|
|
Grave colestasi di origine paraneoplastica in donna ultraottantenne con linfoma B-cellulare anaplastico misconosciuto
[Severe paraneoplastic cholestasis in a octogenarian woman with unrecognized anaplastic B-cell lymphoma], file e309ade0-f266-3969-e053-3a05fe0a2c94
|
102
|
|
Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact, file e309ade3-a103-3969-e053-3a05fe0a2c94
|
91
|
|
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia, file e309ade3-aa29-3969-e053-3a05fe0a2c94
|
83
|
|
Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1, file e309ade0-f319-3969-e053-3a05fe0a2c94
|
75
|
|
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI, file e309ade3-5542-3969-e053-3a05fe0a2c94
|
71
|
|
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study, file e309ade1-de1b-3969-e053-3a05fe0a2c94
|
66
|
|
The gamma-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells, file e309ade1-9c8e-3969-e053-3a05fe0a2c94
|
64
|
|
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia, file e309ade2-7afd-3969-e053-3a05fe0a2c94
|
64
|
|
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia, file e309ade0-fb3b-3969-e053-3a05fe0a2c94
|
61
|
|
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia, file e309ade3-9b53-3969-e053-3a05fe0a2c94
|
61
|
|
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3, file e309ade0-a4fb-3969-e053-3a05fe0a2c94
|
60
|
|
The anti-leukemic activity of sodium dichloroacetate in p53(mutated/null) cells is mediated by a p53-independent ILF3/p21 pathway, file e309ade2-e097-3969-e053-3a05fe0a2c94
|
59
|
|
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance, file e309ade0-3555-3969-e053-3a05fe0a2c94
|
58
|
|
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics, file e309ade3-9b54-3969-e053-3a05fe0a2c94
|
58
|
|
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death, file e309ade4-2c53-3969-e053-3a05fe0a2c94
|
57
|
|
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project, file e309ade3-f2ff-3969-e053-3a05fe0a2c94
|
52
|
|
Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?, file e309ade3-1f82-3969-e053-3a05fe0a2c94
|
50
|
|
Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors, file e309ade5-1e4d-3969-e053-3a05fe0a2c94
|
45
|
|
The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias, file e309ade4-cc42-3969-e053-3a05fe0a2c94
|
44
|
|
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab, file e309ade4-9228-3969-e053-3a05fe0a2c94
|
41
|
|
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group, file 396d8d7f-9a74-469e-a4f6-6cec0e4ee83d
|
40
|
|
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12, file e309ade2-3787-3969-e053-3a05fe0a2c94
|
39
|
|
Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation, file e309ade2-4af4-3969-e053-3a05fe0a2c94
|
39
|
|
Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report, file e309ade4-a5db-3969-e053-3a05fe0a2c94
|
39
|
|
Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients, file e309ade1-de1f-3969-e053-3a05fe0a2c94
|
36
|
|
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia, file e309ade1-ea3c-3969-e053-3a05fe0a2c94
|
34
|
|
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients, file e309ade3-bfff-3969-e053-3a05fe0a2c94
|
31
|
|
Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma, file e309ade1-de23-3969-e053-3a05fe0a2c94
|
29
|
|
microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters, file e309ade5-72a0-3969-e053-3a05fe0a2c94
|
27
|
|
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report, file e309ade2-b0e5-3969-e053-3a05fe0a2c94
|
16
|
|
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus, file e309ade2-b2dd-3969-e053-3a05fe0a2c94
|
12
|
|
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study, file e309ade2-ae29-3969-e053-3a05fe0a2c94
|
11
|
|
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study, file e309ade2-de9b-3969-e053-3a05fe0a2c94
|
11
|
|
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile, file e309ade5-0cde-3969-e053-3a05fe0a2c94
|
11
|
|
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results, file e309ade2-eec3-3969-e053-3a05fe0a2c94
|
10
|
|
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib, file e309ade4-8445-3969-e053-3a05fe0a2c94
|
10
|
|
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report, file e309ade5-1fa5-3969-e053-3a05fe0a2c94
|
10
|
|
The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation, file 3a4199b0-d860-42eb-b817-514e25ea4cff
|
9
|
|
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients, file 6e2a4353-ba54-46da-be08-bcdb37bd10f2
|
9
|
|
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival, file e309ade0-3c3e-3969-e053-3a05fe0a2c94
|
9
|
|
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI, file e309ade4-0df4-3969-e053-3a05fe0a2c94
|
8
|
|
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients, file e309ade4-8121-3969-e053-3a05fe0a2c94
|
8
|
|
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group, file e309ade4-f476-3969-e053-3a05fe0a2c94
|
8
|
|
Potential clinical application of rhGM-CSF in acute myeloid leukemia based on its biological activity and receptor interaction, file e309ade2-a7cd-3969-e053-3a05fe0a2c94
|
7
|
|
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia, file e309ade5-1d7e-3969-e053-3a05fe0a2c94
|
7
|
|
TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype, file 7750689d-3099-4e34-af6a-bee05a77ee1b
|
6
|
|
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs, file a69b35ed-cfdf-4d8d-88a1-051265bcbeec
|
6
|
|
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study, file e309ade4-dcb8-3969-e053-3a05fe0a2c94
|
6
|
|
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL, file e3d8e54b-d987-4755-b9de-e3337a9ce8db
|
6
|
|
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study, file 9822df08-d8c5-4c82-9636-c6680fe6d994
|
5
|
|
Simian virus 40 efficiently infects human T lymphocytes and extends their lifespan, file e309ade0-3348-3969-e053-3a05fe0a2c94
|
5
|
|
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real-Life Campus CLL Study, file edfe91e8-ebc4-42d4-8285-8b3c27e4b683
|
5
|
|
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy, file e309ade1-13a7-3969-e053-3a05fe0a2c94
|
4
|
|
Dasatinib plus Nutlin-3 shows synergistic anti-leukemic activity in both p53wild-type and p53mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway., file e309ade1-7de8-3969-e053-3a05fe0a2c94
|
4
|
|
Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma, file e309ade1-9dea-3969-e053-3a05fe0a2c94
|
4
|
|
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study, file e309ade4-e183-3969-e053-3a05fe0a2c94
|
4
|
|
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations, file e309ade0-ea77-3969-e053-3a05fe0a2c94
|
3
|
|
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness, file e309ade1-751c-3969-e053-3a05fe0a2c94
|
3
|
|
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia, file e309ade2-c690-3969-e053-3a05fe0a2c94
|
3
|
|
Minimal morphological criteria for defining bone marrow dysplasia: A basis for clinical implementation of WHO classification of myelodysplastic syndromes, file e309ade3-d6df-3969-e053-3a05fe0a2c94
|
3
|
|
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study, file 71055d29-5b0e-4f3b-b568-e5ae5e5d578a
|
2
|
|
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study, file 78ce0019-3f97-4c9f-b717-58f0eb312c75
|
2
|
|
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z), file e309ade0-f0c6-3969-e053-3a05fe0a2c94
|
2
|
|
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”, file e309ade1-2055-3969-e053-3a05fe0a2c94
|
2
|
|
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile, file e309ade1-b223-3969-e053-3a05fe0a2c94
|
2
|
|
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study, file 2876484b-b8b3-49f6-bbb1-0478cac48a9d
|
1
|
|
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study, file 2f0634ed-b023-4600-8726-d1407826bbf3
|
1
|
|
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY, file 56029c5e-783e-4443-986b-9ebe2578d446
|
1
|
|
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model, file 91a5744b-117d-4b86-9dc5-d018c5f08529
|
1
|
|
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review, file e309ade0-2f1b-3969-e053-3a05fe0a2c94
|
1
|
|
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients, file e309ade0-2f1c-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade0-3479-3969-e053-3a05fe0a2c94
|
1
|
|
Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD, file e309ade0-3cb0-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade0-465c-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade0-a3bc-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade0-a475-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade0-a476-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade2-ce96-3969-e053-3a05fe0a2c94
|
1
|
|
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group, file e309ade4-8d1a-3969-e053-3a05fe0a2c94
|
1
|
| Totale |
3.545 |